[
    "{\"step_by_step_thinking\": \"Based on the information provided in the documents, tebentafusp has shown promising clinical activity and significant improvement in overall survival in patients with metastatic uveal melanoma. It has been described as the first FDA-approved agent for metastatic uveal melanoma and has the potential to change the standard of care for treating this disease. Therefore, the answer is A. yes.\", \"answer_choice\": \"A\"}"
]